“VeriStrat appears to be a robust assay and should be used for EGFR wild-type patients with squamous cell lung cancer,” says study author Glenwood D. Goss, MD, professor of medicine and an oncologist in the division of medical oncology at the University of Ottawa. Biodesix presented data relating to immunotherapy selection, afatinib efficacy.
GenomeWeb story: Biodesix receives two positive coverage decisions for VeriStrat.
Adoption of GeneStrat by oncologists is helping to drive greater adoption of VeriStrat, Biodesix’s proteomic test for assessing a patient’s prognosis and predicting response to drug treatment.
“The results on this study are particularly exciting, as they suggest that we may be able to identify patients most likely to benefit from anti-PD-1 therapies.”